Multinational Healthcare Investment in Norway: Fulfilling Potential
An in-depth Report
AmCham proudly presents Multinational Healthcare Investment in Norway: Fulfilling Potential, assessing Norway’s ability to grow its engagement within a life-saving – and particularly competitive – global industry.
Norwegian authorities have repeatedly outlined both a desire and need for cooperation and intensified interaction between private healthcare industry and public actors. This report, using a combination of qualitative interviews and quantitative analysis, provides healthcare industry perspectives on Norway’s greatest existing barriers – and most promising recommendations for growth.
Available in both English and Norwegian, the report was authored by Oslo Economics’ Erik Magnus Sæther and his team on behalf of AmCham Norway.
The Healthcare Industry's Contributions Within Norway
The multinational healthcare industry plays a key role in the provision of high-quality, efficient, and equitable care to the Norwegian population.
It also makes a substantial contribution to the Norwegian economy, providing high quality jobs and supporting additional value creation through investment in research and development of new technologies and medicines.
Skilled Jobs
Innovative Treatments
Increased Length & Quality of Life
Welfare System Efficiency
Capital Investments
Exports
Direct Jobs
The private healthcare industry directly employs 5,800 people in Norway
There is a mutual interest from both private industry and the Norwegian government to establish a flourishing healthcare industry in Norway, as is indicated by recent Government publications:
Government Ambitions
This report outlines how the industry hopes to assist in achieving these goals, and work as a solid partner to the public healthcare sector.
Four Main Areas of focus to acheive a more competitive and sustainable healthcare sector (as outlined in the Whitepaper on the Healthcare Industry)
Signals of Existing Barriers
Despite the sector’s significant contributions to the Norwegian economy and society, international comparisons reveal that there is still untapped potential. Several barriers emerge as key to understanding and unlocking this potential.
Spending
As compared to similarly positioned countries, Norway’s low level of government spending on pharmaceuticals represents a low degree of access to innovative treatments.
Pharmaceutical spending as a % of GDP:
Investment
Investment in pharmaceutical R&D and pharmaceutical exports across the Nordic Countries:
Recommendations
Political vision
Joint Life Sciences forum
Value in innovation
Holistic approach to HTAs
Lighthouses of excellence
Invest in existing areas of strength
Risk sharing for faster access
Enact alternative financing schemes
Leverage health registry data
Allow access and defragment
Regional cooperation
Increase Nordic specialization
Report Sponsors:
